samedan logo
 
 
spacer
home > ict > autumn 2020 > the colours of change
PUBLICATIONS
International Clinical Trials

The Colours of Change

Some time ago, a survey was conducted on clinical trial professionals to determine what concerns worried the industry most, experts from pharmaceutical company sponsors, contract research organisations, site representatives, and vendors were consulted. Despite all the great work by these collective groups, an overwhelming number of studies fail for the simple reason that not enough patients stick with them (1). A whopping 85% of studies, in fact, according to Forte Research (2).

Once the results were assessed, ranked fourth behind the likes of trial complexity, regulatory frameworks, and increasing costs, was patient recruitment and retention.

Then, early this year, in a moment of history we are unlikely to forget, COVID-19 hit. Suddenly hospitals and healthcare facilities the world over were sent into pandemic pandemonium, and as we scrabbled for solutions many non-essential clinical trials were put on hold and their patients left in limbo.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Chris Wells is an accomplished travel specialist, event planner, creative thinker, and patient pioneer. Having spent years building programmes in the healthcare and technology sectors, Chris dedicates every minute of every day to better understand and eradicate the burden of clinical trial participation on patients and their families. As Director of Patient Concierge Services at Illingworth Research Group, their PatientGO division works tirelessly to ensure patients receive the optimum home-to-site experience. This helps to reduce study dropout, relieves the pressure on sites, and gives the medicines of the future a fighting chance of helping humanity’s most challenging and deadly diseases.

Print this page
Send to a friend
Privacy statement
News and Press Releases

New laboratory and regulatory services for biotech customers

USA/Germany, September 21, 2020. Gerresheimer adds essential laboratory and regulatory services to its broad portfolio of products, solutions and services for biotech companies. Specialized laboratory technicians and an experienced team of further specialists offer these services in the two innovation and technology centers in Bünde (Germany) and Vineland (New Jersey/USA). Gx Biological Solutions offers full service for biotech companies regarding product development of primary packaging and drug delivery solutions, material and functional testing as well as comprehensive regulatory support. The partnership with Gerresheimer shortens the time to market for pharmaceutical companies, minimizes risks and saves resources.
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement